Treats obsessions and compulsions. ANDA 217917, held by Bionpharma. Fluvoxamine Maleate.
As of Nov 16, 2026, ANDA 217917 (Fluvoxamine Maleate), held by Bionpharma, was first approved by FDA on Jan 22, 2024, with 0 approved supplements and 0 published complete response letters.
Fluvoxamine maleate tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD). 1.1 Obsessive-Compulsive Disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 22, 2024 | Original application | Approved | None posted |
| Fluvoxamine Maleate25MG · tablet;oral | Fluvoxamine Maleate | Rx |
| Fluvoxamine Maleate50MG · tablet;oral | Fluvoxamine Maleate | Rx |
| Fluvoxamine Maleate100MG · tablet;oral | Fluvoxamine Maleate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters